8-K: Hepion Pharmaceuticals Acquires Gravitas Life Sciences

Hepion Pharmaceuticals has acquired Gravitas Life Sciences, a clinical-stage biotech firm, for $2 million in cash and 25 million shares, appointing new CEO and CFO.

Summary

• Hepion Pharmaceuticals, Inc. acquired all membership interests of Gravitas Life Sciences, LLC (GLS) on October 6, 2026.
• The acquisition was completed for $2,000,000 in cash and 25,000,000 shares of Hepion's common stock.
• GLS is a clinical-stage biotechnology company focused on immunology and inflammation, with a lead candidate GV104 (nalmefene buccal film) for opioid overdose prophylaxis.
• GLS also has GV023 (oral infliximab) in preclinical development for inflammatory conditions.
• The transaction involved a related party transaction due to overlapping management and shareholder interests.
• Effective October 9, 2026, Sireesh Appajosyula was appointed CEO and Gary Stetz was appointed CFO of Hepion Pharmaceuticals.
• The company is also addressing a promissory note with Canton Strategic Holdings, Inc. as part of the acquisition.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, driven by a strategic acquisition and leadership changes, though the financial details and integration risks warrant close observation.

Positives

• Strategic acquisition of Gravitas Life Sciences, adding clinical-stage assets in immunology and inflammation.
• GV104, a nalmefene buccal film, has an active IND for prophylaxis of respiratory and/or central nervous system depression from high-potency opioids.
• GV023, an oral formulation of infliximab, has received positive scientific advice from the MHRA for its preclinical development.
• Appointment of Sireesh Appajosyula as CEO and Gary Stetz as CFO brings experienced leadership to the company.
• The acquisition was approved by disinterested members of the Board and a fairness opinion was obtained from Ryan Valuation Services.

Negatives

• The acquisition involves a significant issuance of 25,000,000 shares of common stock, potentially diluting existing shareholders.
• The transaction constitutes a related party transaction, requiring careful scrutiny and disclosure.
• GLS has deprioritized a previous clinical program for pruritus in primary biliary cholangitis.
• The FDA has identified extractables and leachables studies and elemental impurities as required for the GV104 NDA, and commercial-scale registration batches are not planned until 2027.
• Initiation of a first-in-human study for GV023 requires further guidance in 2027 planning.

Risks

• The Buyer Closing Shares issued as part of the consideration are subject to a lock-up period until six months post-closing or registration.
• The shares are subject to forfeiture under certain circumstances described in the Purchase Agreement.
• Potential integration challenges in combining Hepion and Gravitas Life Sciences operations and development pipelines.
• Regulatory risks associated with the development and approval of GV104 and GV023.
• The company's reliance on the 505(b)(2) NDA pathway for GV104, which still requires significant CMC work and studies.
• The need for further guidance in 2027 for the GV023 first-in-human study and CMC programs.

Future Outlook

GLS intends to file an NDA for GV104 after conducting CMC work. Commercial-scale registration batches for extractables and leachables studies are planned to begin in 2027. GLS intends to obtain further guidance in 2027 for planning CMC and first-in-man programs for GV023.

Management Comments

• The disinterested members of the Board determined that the terms of the Purchase Agreement are fair to, and in the best interests of, the Company and its stockholders.
• Ryan Valuation Services provided a fairness opinion stating that the Purchase Consideration is fair, from a financial point of view, to the Company and its stockholders.

Industry Context

StockSavvy.ai notes that this acquisition aligns with the trend of consolidation in the biotechnology sector, particularly among companies seeking to bolster their clinical pipelines with promising assets. The focus on immunology, inflammation, and novel drug delivery platforms like transmucosal films and oral biologics reflects key areas of innovation and investment in the pharmaceutical industry.

Management Changes

Related Party Transactions

• The acquisition of Gravitas Life Sciences, LLC involved Vincent LoPriore, Gary Stetz, Sireesh Appajosyula, and Chase LoPriore, who are directors of Hepion Pharmaceuticals and also officers of GLS and shareholders of the Sole Member (Gravitas Collective Corp.).
• Gary Stetz, a director of Hepion, is also CEO of President Street Global, LLC, which acted as an advisor to Hepion in the transaction.
• Vincent LoPriore, Executive Chairman of Hepion, is an investment manager at Gravitas Capital LP, a principal stockholder of Hepion, and may indirectly benefit from compensation received by President Street Global, LLC.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of 25,000,000 shares of common stock as part of the acquisition consideration.
• Existing shareholders' voting power may be affected by the significant share issuance.
• Employees of both Hepion and Gravitas Life Sciences may face integration challenges and potential restructuring.
• Creditors and suppliers may be impacted by the financial implications of the acquisition and the assumption of certain obligations.

Next Steps

• Complete CMC work for GV104.
• Begin production of commercial-scale registration batches for extractables and leachables studies in 2027.
• Obtain further guidance in 2027 for GV023 CMC and first-in-man programs.
• File an NDA for GV104.
• Initiate first-in-human study for GV023.

Key Dates

Recommendation

The acquisition of Gravitas Life Sciences adds promising clinical-stage assets, particularly GV104, which could be a significant value driver. However, the substantial share issuance for the acquisition, the related-party transaction complexities, and the remaining development and regulatory hurdles for the acquired assets warrant a cautious 'hold' stance. Investors should monitor the integration progress, clinical trial results, and regulatory feedback closely.

Keywords

Acquisition, Biotechnology, Clinical-stage, Immunology, Inflammation, Nalmefene, Infliximab, Drug Development